Evidence map›Paper›PMID 35841410›Full record

Trial reportCancer chemotherapy and pharmacology2022

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.

Kazuhiko Nakagawa, Edward B Garon, Ling Gao, Sophie Callies, Annamaria Zimmermann, Richard Walgren, Carla Visseren-Grul, Martin Reck

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer chemotherapy and pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02411448 (A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02411448 phase3active not recruitingnot on this map

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

TypeinterventionalSponsorEli Lilly and CompanyRan2015 to 2026Enrolled545ConditionsMetastatic Non-Small Cell Lung CancerArmsRamucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Kazuhiko NakagawaDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama City, 377-2, Ohno-higashi, Osaka, 589-8511, Japan. nakagawa@med.kindai.ac.jp.ORCID 0000-0003-1284-9776
Edward B GaronDavid Geffen School of Medicine at University of California Los Angeles, Translational Research in Oncology US Network, Los Angeles, CA, USA.
Ling GaoEli Lilly and Company, Bridgewater, USA.
Sophie CalliesEli Lilly and Company, Paris, France.
Annamaria ZimmermannEli Lilly and Company, Indianapolis, IN, USA.
Richard WalgrenEli Lilly and Company, Indianapolis, IN, USA.
Carla Visseren-GrulEli Lilly Netherlands, Utrecht, The Netherlands.
Martin ReckLungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
Eli Lilly (United States) · USEli Lilly (Netherlands) · NLGerman Center for Lung Research · DEKindai University · JPUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn RELAY, ramucirumab plus erlotinib (RAM + ERL) improved progression-free survival (PFS) in patients with untreated, metastatic, EGFR-mutated, non-small cell lung cancer (NSCLC). Here, we present the exposure-response relationship of RAM from RELAY.

methodsPatients received ERL (150 mg/day) with either RAM (10 mg/kg) or placebo (PBO + ERL) every 2 weeks (Q2W). A population pharmacokinetic model predicted RAM minimum concentration after first dose (C

resultsAnalyses included 216 patients treated with RAM + ERL and 225 patients treated with PBO + ERL. Adjusting for significant baseline covariates, no exposure-efficacy relationship was identified in RELAY: PFS hazard ratio (mean, 95% confidence intervals) for the C

conclusionsNo association was observed between RAM exposure and response, suggesting that the RELAY regimen of RAM 10 mg/kg Q2W with ERL is an optimized, efficacious, and safe first-line treatment for patients with untreated, metastatic, EGFR-mutated NSCLC.

trial registrationClinicalTrials.gov, NCT02411448.

Indexed as

Carcinoma, Non-Small-Cell LungHypertensionLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsErlotinib HydrochlorideHumansMutationRamucirumabAntibodies, Monoclonal, HumanizedEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideRamucirumabExposure–responseNon-small cell lung cancerPharmacokineticsRamucirumab

Identifiers

PMID35841410
PMCPMC9360106
OpenAlexW4285587076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.